ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OBD Oxford Biodynamics Plc

7.90
0.12 (1.54%)
23 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.12 1.54% 7.90 7.66 7.82 7.90 7.60 7.90 4,070,489 16:35:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.34M -10.83M -0.0535 -1.44 15.58M

Oxford BioDynamics PLC Results of GM

03/04/2024 12:57pm

RNS Regulatory News


RNS Number : 1898J
Oxford BioDynamics PLC
03 April 2024
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.

UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO SHAREHOLDERS OF THE COMPANY DATED 14 MARCH 2024.

 

Oxford BioDynamics PLC

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Result of General Meeting

Director/PDMR Dealings

3 April 2024 - Oxford BioDynamics PLC (AIM: OBD), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform announces that both resolutions proposed at the General Meeting of the Company, held earlier today, were duly passed.

 

Further to the passing of the resolutions at the General Meeting, application has been made for 18,234,454 new Ordinary Shares (comprising the VCT/EIS Placing Shares to be issued pursuant to the Placing) to be admitted to trading on AIM ("VCT/EIS Admission"). Application has also been made for 91,317,781 new Ordinary Shares (comprising the General Placing Shares, the Subscription Shares and the PrimaryBid Shares to be issued pursuant to the Placing, the Subscriptions and the PrimaryBid Offer) to be admitted to trading on AIM ("General Admission").

 

It is expected that VCT/EIS Admission will take place, and trading in the VCT/EIS Placing Shares will commence, at 8.00 a.m. on 5 April 2024 and that General Admission will take place, and trading in the General Placing Shares, the Subscription Shares and the PrimaryBid Shares will commence at 8.00 a.m. on 8 April 2024.

 

Following VCT/EIS Admission, the Company's issued ordinary share capital and total voting rights will consist of 220,537,869 Ordinary Shares. Following General Admission, the Company's issued ordinary share capital and total voting rights will consist of 311,855,650 Ordinary Shares. These figures should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The total New Ordinary Shares subscribed for pursuant to the Placing, the Subscriptions and the PrimaryBid Offer by the Directors and PDMRs who are participating in the Fundraising, are set out below:

Director/PDMR

Existing beneficial shareholding

Fundraising Shares

Beneficial shareholding following the Fundraising

Shareholding as a percentage of the Enlarged Share Capital

Dr Alexandre Akoulitchev

6,603,082

333,333

6,936,415

2.22%

Dr Jon Burrows

700,000

388,888

1,088,888

0.35%

Stephan Diggle1

27,431,756

2,222,222

29,653,978

9.51%

Thomas Guiel

365,000

258,888

623,888

0.20%

Dr Ewan Hunter

136,363

55,555

191,918

0.06%

Paul Stockdale

331,818

166,666

498,484

0.16%

Matthew Wakefield2

1,022,727

277,777

1,300,504

0.42%

 

1 Stephen Diggle's beneficial shareholding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.

2 Matthew Wakefield's beneficial shareholding includes shares owned by his wife, Mrs Carla Wakefield.

 

Following on from the Company's announcement on 13 March 2024, Baden Hill, a related party of the Company, will receive commission of £167,135 in relation to their role as joint broker on the Fundraising.

 

 

 

Director/PDMR Dealings

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Matthew Wakefield

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

277,777

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Dr Jon Burrows

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

388,888

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Dr Alexandre Akoulitchev

2

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

333,333

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Paul Stockdale

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

166,666

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Vulpes Investment Management (a PCA of Stephen Diggle) through Vulpes Testudo Fund

2

Reason for the notification

a)

Position/status

Person closely associated with Non-Executive Director

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

2,222,222

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2023

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Thomas Guiel

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

258,888

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities / person closely associated

a) 

Name

Dr Ewan Hunter

2

Reason for the notification

a)

Position/status

Chief Data Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

 

Ordinary Shares of 1p par value each

  

ISIN: GB00BD5H8572

b)

Nature of the transaction

Purchase

c)

 

Price(s) and volume(s)

 Price(s)

Volume(s)

£0.09

55,555

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Off market

 

 

 

For further details please contact:

 

Oxford BioDynamics PLC

Jon Burrows, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital - Nominated Adviser and Joint Broker

Advisory: Stephane Auton / Iain Sexton

Broking: Fiona Conroy

 

+44 (0)20 7408 4090

Baden Hill (a trading name for Northland Capital Partners Limited) - Joint Broker

Alex Schlich

 

+44 (0)20 3951 8907

WG Partners - Joint Broker

David Wilson / Claes Spång / Sateesh Nadarajah / Erland Sternby

 

+44 (0)20 3705 9330

Instinctif Partners

Tel: +44 (0)20 7457 2020

Melanie Toyne-Sewell / Jack Kincade

 

OxfordBioDynamics@instinctif.com

 

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which was launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQKNBPDBKDPQK

1 Year Oxford Biodynamics Chart

1 Year Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

Your Recent History

Delayed Upgrade Clock